Nevertheless, to assess the clinical usefulness of our platform, we randomized nine mice carrying this patient’s tumor into three treatment groups receiving vemurafenib (BRAF inhibitor), trametinib (MEK inhibitor) or a combination, mimicking the clinical trial design. This evidence concerns the gene BRAF and neoplasm.